Brigatinib is used to fight NSCLC that’s spread and is ALK-positive. It works by stopping ALK signaling, which is a big reason cancer cells grow in this kind of cancer. You can get it in three doses: 30, 90, or 180 mg, all in the form of film-coated pills.
For NSCLC patients, the starting dose is one 90 mg pill a day for the first week, then it’s up to 180 mg a day after that. The pills come in bottles, with each one holding 30 tablets.
Reviews
There are no reviews yet.